This CPB has been revised to state that bendamustine is considered experimental and investigational for acute myeloid leukemia, breast cancer, brain metastases from solid tumors, colorectal cancer, hairy cell leukemia, head and neck cancer, immune thrombocytopenic purpura, Langerhans cell sarcoma, myelodysplastic syndrome, non-small cell lung cancer, and small cell lung cancer.